The global market for transdermal drug delivery systems should grow from $6.4 billion in 2021 to $7.8 billion by 2026, at a compound annual growth rate (CAGR) of 4.2% for the period of 2021-2026.
Report Scope
This report aims to provide a comprehensive study of the global market for transdermal drug delivery technologies/systems. It provides a detailed description of the different types of transdermal drug delivery systems (passive and active) and the current and historical market revenues.
Transdermal drug delivery technologies/systems include passive transdermal drug delivery and active transdermal drug delivery. Passive transdermal drug delivery technologies/systems are segmented into the matrix, reservoir and other transdermal drug delivery technologies/systems.
This report also offers a detailed study of therapeutic applications for transdermal drug delivery: pain, central nervous system (CNS) disorders, hormonal applications, smoking cessation, motion sickness, cardiovascular disorders and others. An in-depth analysis of the global market for transdermal drug delivery technologies/systems includes historical data and market projection of sales by technology/system type, therapeutic application, end-user and region.
For an in-depth understanding of the market, profiles of market participants, key marketed products, competitive landscape, key competitors and respective market shares have been provided. This report also discusses driving and restraining factors of the global transdermal drug delivery technology/device market.
The Report Includes
- 60 tables
- An overview of the global markets for transdermal drug delivery (TDD) technologies/systems within the pharmaceutical industry
- Analyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Market outlook and forecast trends of clinical application areas and end user segments of transdermal drug delivery technologies/systems
- Estimation of market size and revenue forecast for TDD market, and corresponding market share analysis by technology/system type, therapeutic application, end-user, and region
- Discussion of the key market dynamics (DROs), industry structure, regulatory approval, market deterrents, unmet needs and other factors driving opportunities in pharmaceutical research
- Review of patents, new developments and emerging technologies, clinical trials for many pipeline products, and potential markets for future developments
- Impact analysis of the Covid-19 pandemic on transdermal drug delivery systems market as against the overall pharmaceuticals industry
- Insight into recent industry activities, competitive landscape of the major players operating within the global market, and their corresponding company share analysis
- Profile descriptions of the leading drug delivery companies including AbbVie, Dr. Reddy's Laboratories Ltd., Bayer, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Teva Pharmaceutical, and Viatris
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of This Report
- Methodology and Information Sources
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Overview of Transdermal Drug Delivery Systems
- Mechanism of Transdermal Drug Delivery
- Advantages of Transdermal Drug Delivery
- Disadvantages of Transdermal Drug Delivery
- TDSS Types/Forms
- Transdermal Patch
- Transdermal Gel
- Transdermal Spray
- Transdermal Ointment
- TDDS Technology Types
- Passive TDDS
- Types of Passive TDDS
- Active TDDSs
- Types of Active TDDS
- Clinical Application of TDDS
- Pain Management
- CNS Disorders
- Hormonal Applications
- Smoking Cessation
- Motion Sickness
- Cardiovascular Diseases (CVD)
- Others
- End Users of TDDSs
- Home Care Settings
- Hospitals and Healthcare Clinics
Chapter 4 Market Breakdown by Technology Type
- Global Market for TDDSs by Type
- Passive TDDSs by Type
- Passive TDDSs by Region
- Active TDDSs by Region
Chapter 5 Market Breakdown by Application
- Global Market for TDDS by Therapeutic Application
- Market Size and Forecast by Therapeutic Application Type
- Pain
- CNS Disorders
- Hormonal Applications
- Smoking Cessation
- Motion Sickness
- CVD
- Other Therapeutic Applications for TDDSs
Chapter 6 Market Breakdown by Region
- Global Markets for TDDSs by Region
- North America
- Europe
- Asia-Pacific
- RoW
Chapter 7 Market Breakdown by End User
- Global Markets for TDDS by End User
- Market Size and Forecast by End User
- North American End-User Market
- European End-User Market
- Asia-Pacific End-User Market
- RoW
Chapter 8 New Developments and Emerging Technologies
- Innovative Transdermal Technologies
- Technologies by Hisamitsu Pharmaceutical Co. Inc.
- Technologies by 4 P Therapeutics (Nutriband)
- Technologies by Corium Inc.
- Technologies by Tapemark
- Emerging Technologies and Applications for TDDS
- Company/System
Chapter 9 Market Dynamics
- Market Trends and Growth Drivers
- Aging Population
- Technology Innovations and New Product Development
- Increasing Awareness
- Large Unpenetrated Addressable Market
- Market Restraining Factors
- Product Development and Manufacturing Challenges
- The Barrier Nature of the Skin
- Side Effects
- High Cost of Drug Development and Pricing Pressure
- Market opportunity
- Repositioning of Currently Marketed Products
Chapter 10 Competitive Landscape
- Overview
- Key Available TDDSs
- Pain Management
- Hormone Replacement Therapy
- Female Contraception
- CNS Disorders
- Smoking Cessation
- Motion Sickness
- For Cardiovascular Diseases
- Overactive Bladder
- Other Applications
- Global Market Shares of Leading Companies
- Recent Industry Activities
- Product Launches and Approvals
- Agreements and Collaborations
- Acquisitions and Mergers
- Others
Chapter 11 Impact of COVID-19 Pandemic
Chapter 12 Company Profiles
- Abbvie Inc.
- Acrux Ltd.
- Alvogen
- Amneal Pharmaceuticals Inc.
- Bayer Healthcare Pharmaceuticals
- Boehringer Ingelheim International Gmbh
- Dr. Reddy's Laboratories Ltd.
- Endo Pharmaceuticals Inc.
- Glaxosmithkline Plc
- Hisamitsu Pharmaceutical Co. Inc.
- Johnson & Johnson
- Kyowa Kirin Co. Ltd.
- Lavipharm S. A.
- Luye Pharma Group Ltd.
- Novartis Ag
- Noven Pharmaceuticals Inc.
- Perrigo Company Plc
- Purdue Pharma Lp
- Tapemark
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Uspharma Ltd.
- Vertical Pharmaceuticals Llc
- Viatris Inc.
Chapter 13 Appendix: Acronyms
List of Tables
Summary Table: Global Market for Transdermal Drug Delivery Systems, by Type, Through 2026
Table 1: Difference Between Topical and Transdermal Drug Delivery Systems
Table 2: Currently Marketed Transdermal Drugs
Table 3: Classification of Transdermal Drugs for Pain Management
Table 4: OTC and Prescription Classifications
Table 5: Classification of Transdermal Drugs Used for CNS Disorders
Table 6: Classification of Transdermal Drugs Used for Motion Sickness
Table 7: Classification of Transdermal Drugs Used for CVD
Table 8: Classification of Transdermal Drugs for Other Applications
Table 9: Global Market for Transdermal Drug Delivery Systems, by Type, Through 2026
Table 10: Global Market for Passive Transdermal Drug Delivery Systems, by Type, Through 2026
Table 11: Global Market for Passive Transdermal Drug Delivery Systems, by Region, Through 2026
Table 12: Global Market for Active Transdermal Drug Delivery Systems, by Region, Through 2026
Table 13: Global Market for Transdermal Drug Delivery Systems, by Therapeutic Application, Through 2026
Table 14: Global Market for Transdermal Drug Delivery Systems for Pain Management, by Region, Through 2026
Table 15: Global Market for Transdermal Drug Delivery Systems Indicated for CNS Disorders, by Region, Through 2026
Table 16: Global Market for Transdermal Drug Delivery Systems for Hormonal Applications, by Region, Through 2026
Table 17: Global Market for Transdermal Drug Delivery Systems for Smoking Cessation, by Region, Through 2026
Table 18: Global Market for Transdermal Drug Delivery Systems for Motion Sickness, by Region, Through 2026
Table 19: Global Market for Transdermal Drug Delivery Systems for CVD, by Region, Through 2026
Table 20: Global Market for Transdermal Drug Delivery Systems for Other Therapeutic Applications, by Region, Through 2026
Table 21: Global Market for Transdermal Drug Delivery Systems, by Region, Through 2026
Table 22: Elder Population, Selected European Countries
Table 23: Global Market for Transdermal Drug Delivery Systems, by End User, Through 2026
Table 24: North American Market for Transdermal Drug Delivery Systems, by End User, Through 2026
Table 25: European Market for Transdermal Drug Delivery Systems, by End User, Through 2026
Table 26: Asia-Pacific Market for Transdermal Drug Delivery Systems, by End User, Through 2026
Table 27: RoW Market for Transdermal Drug Delivery Systems, by End User, Through 2026
Table 28: Industry-Funded Clinical Trials for Transdermal Drug Delivery Systems, 2021
Table 29: Total Elder Population, by Country, 2008 and 2018
Table 30: Key Manufacturers, Transdermal Drug Delivery Systems for Pain Management
Table 31: Key Manufacturers, Transdermal Drug Delivery Systems for Hormonal Replacement Therapy
Table 32: Key Manufacturers, Transdermal Drug Delivery Systems for Female Contraception
Table 33: Key Manufacturers of Transdermal Drug Delivery Systems for CNS Disorders
Table 34: Key Manufacturers of Transdermal Drug Delivery Systems for Smoking Cessation
Table 35: Key Manufacturers of Transdermal Drug Delivery Systems for Motion Sickness
Table 36: Key Manufacturers of Transdermal Drug Delivery Systems for CVD
Table 37: Key Manufacturers of Transdermal Drug Delivery Systems for Overactive Bladder
Table 38: Key Manufacturers of Transdermal Drug Delivery Systems for Other Applications
Table 39: Leading Company’s Share in Transdermal Drug Delivery Systems, 2020
Table 40: AbbVie Inc.: Transdermal Drug Delivery Product Portfolio
Table 41: Alvogen: Transdermal Drug Delivery Product Portfolio
Table 42: Amneal Pharmaceuticals Inc.: Transdermal Drug Delivery Product Portfolio
Table 43: Bayer Healthcare Pharmaceuticals: Transdermal Drug Delivery Product Portfolio
Table 44: Boehringer Ingelheim International GmbH: Transdermal Drug Delivery Product Portfolio
Table 45: Endo Pharmaceuticals Inc.: Transdermal Drug Delivery Product Portfolio
Table 46: GlaxoSmithKline PLC: Transdermal Drug Delivery Product Portfolio
Table 47: Hisamitsu Pharmaceutical Co. Inc.: Rx Product Portfolio
Table 48: Hisamitsu Pharmaceutical Co. Inc.:OTC Pain Relief Products
Table 49: Johnson & Johnson: Transdermal Drug Delivery Product Portfolio
Table 50: Kyowa Kirin Co. Ltd.: Transdermal Drug Delivery Product Portfolio
Table 51: Lavipharm: Transdermal Drug Delivery Product Portfolio
Table 52: Luye Pharma Group Ltd.: Transdermal Drug Delivery Product Portfolio
Table 53: Novartis AG: Transdermal Drug Delivery Product Portfolio
Table 54: Perrigo Company PLC.: Transdermal Drug Delivery Product Portfolio
Table 55: Purdue Pharma LP: Transdermal Drug Delivery Product Portfolio
Table 56: Teva Pharmaceutical Industries Ltd.: Transdermal Drug Delivery Product Portfolio
Table 57: UCB S.A.: Transdermal Drug Delivery Product Portfolio
Table 58: USpharma: Transdermal Drug Delivery Product Portfolio
Table 59: Viatris Inc.: Transdermal Drug Delivery Product Portfolio
Table 60: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market for Transdermal Drug Delivery Systems, by Type, 2020-2026
Figure 1: Mechanism of Transdermal Drug Delivery System
Figure 2: Single Layer Drug in Adhesive Transdermal Delivery System
Figure 3: Multi-Layer Drug in Adhesive Transdermal Delivery System
Figure 4: Matrix Transdermal Delivery System
Figure 5: Reservoir Transdermal Delivery System
Figure 6: Global Market Shares of Transdermal Drug Delivery Systems, by Type, 2020
Figure 7: Global Market for Passive Transdermal Drug Delivery Systems, by Type, 2020
Figure 8: Global Market Shares of Passive Transdermal Drug Delivery Systems, by Region, 2020
Figure 9: Global Market Shares of ActiveTransdermal Drug Delivery Systems, by Region, 2020
Figure 10: Global Market Shares of Transdermal Drug Delivery Systems, by Therapeutic Application, 2020
Figure 11: Global Market Shares of Transdermal Drug Delivery Systems for Pain Management, by Region, 2020
Figure 12: Global Market for Transdermal Drug Delivery Systems Indicated for CNS Disorders, by Region, 2020
Figure 13: Global Market Shares of Transdermal Drug Delivery Systems for Hormonal Applications, by Region, 2020
Figure 14: Global Market Shares of Transdermal Drug Delivery Systems for Smoking Cessation, by Region, 2020
Figure 15: Global Market Shares of Transdermal Drug Delivery Systems for Motion Sickness, by Region, 2020
Figure 16: Global Market Shares of Transdermal Drug Delivery Systems for CVD, by Region, 2020
Figure 17: Global Market Shares of Transdermal Drug Delivery Systems for Other Therapeutic Applications, by Region, 2020
Figure 18: Global Market Shares of Transdermal Drug Delivery Systems, by Region, 2020
Figure 19: Global Market Shares of Transdermal Drug Delivery Systems, by End User, 2020
Figure 20: North American Market Shares of Transdermal Drug Delivery Systems, by End User, 2020
Figure 21: European Market Shares of Transdermal Drug Delivery Systems, by End User, 2020
Figure 22: Asia-Pacific Market Shares of Transdermal Drug Delivery Systems, by End User, 2020
Figure 23: RoW Market Shares of Transdermal Drug Delivery Systems, by End User, 2020
Samples
LOADING...
Executive Summary
Transdermal drug delivery systems (TDDSs: gels, patches, films, etc.) are placed on the skin and allow specific drug substances to penetrate into the bloodstream through the layers of the skin. TDDSs have many benefits compared to other methods of drug delivery (oral, injectable, etc.) TDDSs mitigate the hepatic first-pass effect of drugs, offering safety and a better quality of life to the patient. TDDSs are used to treat a wide variety of conditions and diseases, including pain, CNS disorders, hormone imbalance, prevention of nausea and vomiting, cardiovascular diseases (CVD), overactive bladder and several others. Most TDDSs are available in the form of patches.
Transdermal drug delivery (TDD) is still a relative niche segment, currently accounting for a small market share in the overall drug delivery market. However, given the many advantages (ease of use, better patient compliance, improved bioavailability and fewer adverse effects, etc.) over other drug delivery options (oral and injections) TDD has gained increasing attention over the last decade. TDDSs hold huge potential to address the needs of an increasing global elder population, especially in caregiver-intensive conditions and for patients with chronic conditions. Opportunity exists to translate drug needs into a dosage form that is more end-user (patient) and caregiver friendly. Regarding the patent cliff, TDD could make pharmaceutical companies more competitive. For example, a pharmaceutical company that focuses on life cycle management and TDD as a parallel path during development could be in a better position to extend the life of a drug and to strategically introduce a variety of formulations that drive patient preference.
The advent of innovative, new approaches and continuous technology development is the key factor driving growth in the market. The growing number of elder patients and the increasing demand for convenient drug delivery options with easy self-administration are also facilitating the market growth.
TDD biologics (e.g., peptides, proteins, nucleic acids) and the use of new drug delivery devices such as microneedle systems for transdermal drug delivery, have high growth potential and are likely to have more activity in the coming years. The opportunity areas in this market include TDD of large molecules underpinned by a large (multibillion) biologics market, wherein the demand for advanced drug delivery systems is increasing.
Companies Mentioned
- Abbvie Inc.
- Acrux Ltd.
- Alvogen
- Amneal Pharmaceuticals Inc.
- Bayer Healthcare Pharmaceuticals
- Boehringer Ingelheim International Gmbh
- Dr. Reddy's Laboratories Ltd.
- Endo Pharmaceuticals Inc.
- GlaxoSmithKline Plc
- Hisamitsu Pharmaceutical Co. Inc.
- Johnson & Johnson
- Kyowa Kirin Co. Ltd.
- Lavipharm S. A.
- Luye Pharma Group Ltd.
- Novartis Ag
- Noven Pharmaceuticals Inc.
- Perrigo Company Plc
- Purdue Pharma Lp
- Tapemark
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- USpharma Ltd.
- Vertical Pharmaceuticals Llc
- Viatris Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 109 |
| Published | June 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 6.4 Billion |
| Forecasted Market Value ( USD | $ 7.8 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
